Nitric oxide and cardiovascular system

Anadolu Kardiyoloji Dergisi

Volumn 6, Issue 4, 2006, Pages 364-368

  Çengel, Atiye ^a   Şahinarslan, Asife ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Cardiovascular system; Nitric oxide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BETA CAROTENE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PERINDOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINAPRIL; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ANGIOCARDIOGRAPHY; ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EXCRETION; DRUG URINE LEVEL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW MEASUREMENT; GENOTYPE; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SMOKING; THROMBOCYTE AGGREGATION INHIBITION; URINARY EXCRETION; VASCULAR ENDOTHELIUM; VASODILATATION;

CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE;

EID: 33846363851     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90 (suppl): 40L-8L.
2. Tentolouris C, Tousoulis D, Goumas G, Stefanadis C, Davies G, Toutouzas P. L-Arginine in coronary atherosclerosis. Int J Cardiol 2000; 75: 123-8.
3. Gorren ACF, Schrammel A, Schmidt K, Mayer B. Thiols and neuronal nitric oxide synthase: complex formation, competitive inhibition and enzyme stabilization. Biochemistry 1997; 36: 4360-6.
4. Damy T,Ratajczak P, Shah AM, Camons E, Marty I, Hasenfuss G, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004; 363: 1365-7.
5. Paulus WJ, Bronzwaer JG. Myocardial contractile effects of nitric oxide. Heart Fail Rev 2002; 7: 371-83.
6. Gealekman O, Abbasi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 2002; 105: 236-43.
7. Saito T, Hu F, Tayara L, Fahas L, Shennib H, Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H339-45.
8. Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaidenstein R, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101: 1358-61.
9. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
10. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor; in experimental hypertension. Hypertension 1997; 29: 242-7.
11. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon RO 3rd, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 1998; 97: 851-6.
12. Zizek B, Poredos P, Videenik V. Endothelial dysfunction in hypertensive patients and in normotensive offspring subjects with essential hypertension. Heart 2001; 85: 215-7.
13. Kuzkaya N, Weismann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003; 278: 22546-54.
14. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, et al. Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293: 2449-52.
15. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-74.
16. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin- mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96: 786-92.
17. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of the diabetes mellitus: evidence for a protective treatment effect in the West Scotland Coronary Prevention Study. Circulation 2001; 103: 357-62.
18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
19. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000; 404: 787-90.
20. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of a symmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106:987-92.
21. Luft FC. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens. 2002; 11: 59-66.
22. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism 1993; 42: 1027-30.
23. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-7.
24. Stanger O, Weger M. Interactions of homocysteine, nitric okside, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003; 41: 1444-54.
25. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia. Role of tumor necrosis factor-, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003; 23: 418-23.
26. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inemia in humans. Clin Sci 2001; 100: 161-7.
27. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetrical dimethylarginine. Circulation 2001; 104: 2569-75.
28. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med 1998; 49: 31-62.
29. Lowe ER, Everett AC, Lee AJ. Time-dependent inhibition and tetrahydrobiopterin depletion of endothelial nitric-oxide synthase caused by cigarettes. Drug Metab Dispos 2005; 33: 131-8.
30. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG. Heavy and light cigarette smokers have similar dysfunction on endothelial vasoregulatory activity: an in vivo and in vitro correlation. J Am Coll Cardiol 2002; 39: 1758-63.
31. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Rand WM, Udelson JE, et al. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 2001; 38: 1843-9.
32. Dawey PJ, Schulz M, Gliksman M, Dobson M, Aristides M, Stephens NG. Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing(CHAOS trial). Cambridge Heart Antioxidant Study. Am J Cardiol 1998; 82: 414-7.
33. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease(SPACE): randomized placebo controlled trial. Lancet 2000; 356: 1213-8.
34. Kinlay S, Behrendt D, Fang JC, Delagrange D, Morrow J, Witztum JL, et al. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004; 43: 629-34.
35. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-34.
36. Wilmink HW, Stroes ES, Erkelens WD, Gerritsen WB, Wever R, Banga JD, et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000; 20: 185-8.
37. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockage on flow-mediated vasodilation in patients with coronary disease.(BANFF study). J Am Coll Cardiol 2000; 35: 60-6.
38. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003; 41: 1281-6.
39. Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, et al; HOPE Investigators.Effects of ramipril on coronary events in highrisk persons: result of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104: 522-6.
40. Fox KM. EURopean trial On reduction of cardiac events with perindopril in stable coronary Artery disease Investigators. Efficiency of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled multicentre trial (the EUROPE study). Lancet 2003; 362: 782-8.
41. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-22.
42. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
43. Shlipak MG, Chaput LA, Vittinghoff E, Lin F, Bittner V, Knopp RH, Hulley SB. Heart and Estrogen/progestin Replacement Study(HERS) Investigators. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 2003; 146: 870-5.
44. Hsia J, Aragaki A, Bloch M, LaCroix AZ, Wallace R and WHI Investigators. Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiative Observational Study. Am J Cardiol 2004; 93: 673-8.
45. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997; 129: 261-9.
46. Raji A, Seely EW, Bekin SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-8.
47. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-64.
48. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002; 51: 1110-7.